医药产业发展动态

1. 今年中国创新药交出了一份亮眼的成绩单。
This has been a standout year for China's innovative drug industry.
2. 上半年，国家药监局批准38款创新药上市，其中国产创新药31款。
In the first half of the year, China's National Medical Products Administration approved 38 innovative drugs, 31 of which were developed domestically.
3. 同期，国产创新药对海外药企的授权交易达成81笔，披露总金额约1100亿美元。
Over the same period, domestic innovators closed 81 out-licensing deals with global pharma partners, with a disclosed aggregate value of roughly $110 billion.
4. 在全球医药授权交易金额前十中，中国药企占了八席。
Chinese companies claimed eight of the top ten slots in the global licensing deal rankings by value.
5. 理解中国创新药的盈利数据，首先要理解这个行业商业模式的特殊性。
To make sense of these earnings figures, we first need to appreciate the unique economics of the drug innovation business.
6. 它的研发时间以十年计，研发投入以十亿美元计，失败率却极高。
Drug development takes years—often over a decade—costs billions of dollars, and carries a staggering failure rate.
7. 候选药物从Ⅰ期临床走到获得美国FDA批准上市的概率仅7.9%。
Only 7.9% of drug candidates that enter Phase I trials ever win FDA approval.
8. Ⅱ期推进到Ⅲ期不足三成。
And fewer than one in three drugs advance from Phase II to Phase III.
9. 成功上市的新药在专利期内享有独占定价权。
Those that do make it to market are rewarded with exclusive pricing power for the duration of their patent life.
10. 创新药企业的核心资产不是当期产量，而是“管线”。
For an innovative pharma company, the real asset isn't current manufacturing output—it's the pipeline.
11. 管线是指企业手中尚未获批上市、处于不同研发阶段的新药项目组合。
A pipeline is a portfolio of experimental drug candidates, still unapproved and spread across different stages of development.
12. 今年创新药行业的业绩向好不是突然发生的，而是前期多年的投入逐渐进入了收获期。
This year's strong earnings didn't come out of nowhere—they mark the gradual payoff of years, even decades, of sustained R&D investment.
13. 为分摊新药研发的高风险，企业正把研发成果在不同阶段分别变现。
To mitigate the huge risks involved, companies are now monetizing their R&D fruits at multiple stages along the development path.
14. 上市产品有销售收入，在研项目有对外授权的首付款，成熟业务则用现金流反哺研发。
Approved drugs bring in sales revenues, pipeline assets generate upfront licensing fees, and established operations provide steady cash flow to fund further innovation.
15. 第一重共性，是收入结构的双轮驱动：产品销售和对外授权。
The first common thread is a dual-engine revenue model—combining product sales with out-licensing income.
16. 第二重共性，是自我造血能力的普遍形成。
The second is the broad emergence of self-sustaining financial strength.
17. 第三重共性，是出海模式的质变。
The third is a fundamental upgrade in how Chinese companies go global.
18. 过去的授权交易多是把海外权益一次性卖给跨国药企，后续的大部分收益也归对方所有。
In the past, out-licensing usually meant selling overseas rights outright to multinational partners, who then captured most of the downstream value.
19. 今年的几笔大交易则结构不同，中方获得了更多利润分享和主导权。
This year's blockbuster deals tell a different story, with Chinese players securing greater profit-sharing and a stronger say in decision-making.
20. 跨国巨头愿意把利润和主导权分出来，说明中国管线在全球价值链中的议价能力已有实质提升。
That global giants are now willing to share both economics and control is a clear sign that China's pipelines have gained real bargaining power in the global value chain.
21. 第四重共性，是AI在新药研发中的深度应用。
The fourth commonality is the deepening role of AI in drug R&D.
22. AI发现的分子Ⅰ期成功率可达八至九成。
Molecules identified through AI have been shown to achieve Phase I success rates of 80% to 90%.
23. 政策层面，2015年药审改革主要解决审批效率问题。
On the policy side, the 2015 drug review reform was largely about clearing backlogs and speeding up approvals.
24. 今年新一轮政策开始解决审批之后的问题：定价、医保支付和医院准入。
The latest policy push, however, goes a step further—tackling the post-approval hurdles of pricing, reimbursement, and hospital formulary inclusion.
25. 从审批到定价、支付、准入，政策覆盖了创新药商业化的完整链条。
From regulatory clearance to pricing, payer coverage, and patient access, the policy framework now addresses the entire commercial pathway.
26. 未来，政策需持续投入基础研究，推动临床试验数据获美欧监管认可。
Looking ahead, policymakers should keep funding basic research and work toward having Chinese clinical trial data accepted by U.S. and European regulators.
27. 企业应拿出更大魄力做原始创新，也要学会经营全球市场。
Companies, for their part, need to aim higher in true original innovation while also mastering the art of competing in global markets.
28. 资本市场要区分一次性授权收益与可持续经营能力，给长周期、高风险项目更多耐心。
And capital markets should learn to tell one-off licensing windfalls from sustainable operating strength—and show greater patience for long-horizon, high-stakes projects.
29. 中国药企既能持续发现好药、又能把好药卖向全球，今天的盈利拐点才会真正变成产业长期竞争力。
Only when Chinese pharma firms can consistently discover great drugs and successfully commercialize them worldwide will today's profit inflection point evolve into lasting industrial competitiveness.